Login to Your Account

FDA's latest accelerated nod clears Aliqopa, Bayer's lymphoma drug

By Jennifer Boggs
Managing Editor

Thursday, September 14, 2017

Bayer AG's P13K inhibitor, copanlisib, won FDA approval Thursday for use in adults with relapsed follicular lymphoma who have received at least two prior systemic therapies.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription